Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Bioequivalence: Overview01:16

Bioequivalence: Overview

Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Bioequivalence studies: Biowaivers01:13

Bioequivalence studies: Biowaivers

In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
Pharmaceutical Equivalents01:26

Pharmaceutical Equivalents

As defined by regulatory standards, pharmaceutical equivalents require generic drug products to have identical dosage forms and chemically identical active pharmaceutical ingredients (APIs). They must adhere to compendial or applicable standards for potency, content uniformity, disintegration times, and dissolution rates. In the case of modified-release dosage forms, variations in drug content are permissible as long as the delivered amount remains consistent with the innovator drug product.
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence01:27

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Divergent molecular mechanisms underlie differential toxicity of trivalent lanthanum and divalent cadmium in Enchytraeus crypticus.

Ecotoxicology and environmental safety·2026
Same author

NF-κB p65 modulates the promoter activity of large yellow croaker (Larimichthys crocea) interleukin-2.

Developmental and comparative immunology·2026
Same author

Conformation-Adaptive Crown Ether-Polyimides as Superfast and Exceptionally Selective Artificial Na<sup>+</sup> Channels.

Angewandte Chemie (International ed. in English)·2026
Same author

High-Performance Artificial Lithium Channel Enabled by a Brominated Organic Imine Cage.

Angewandte Chemie (International ed. in English)·2026
Same author

Unanticipated Emergence of the Photo-Switchable Cs<sup>+</sup>-Selective Ion Channels From One-Dimensional 18-Crown-6 Arrays.

Angewandte Chemie (International ed. in English)·2026
Same author

Unraveling the Mechanism of Perillyl Alcohol and Its Derivatives as Potent Antifungal Agents against Gray Mold.

Journal of agricultural and food chemistry·2026

Video Experimental Relacionado

Updated: Jul 16, 2026

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System
12:40

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System

Published on: December 7, 2012

Un enfoque no covalente para la formación de hojas beta antiparalelas.

Huaqiang Zeng1, Xiaowu Yang, Robert A Flowers

  • 1Department of Chemistry, Natural Sciences Complex, State University of New York, Buffalo, New York 14260, USA.

Journal of the American Chemical Society
|March 21, 2002
PubMed
Resumen

Los investigadores crearon duplexos híbridos estables utilizando cadenas de péptidos y una plantilla de ADN. Estas estructuras forman hojas beta, evitando la agregación y mostrando una mayor estabilidad en comparación con los componentes individuales.

Más Videos Relacionados

Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

Alternative Methods for the Detection of Superoxide Anion Generation in Platelets
06:35

Alternative Methods for the Detection of Superoxide Anion Generation in Platelets

Published on: March 29, 2024

Videos de Experimentos Relacionados

Last Updated: Jul 16, 2026

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System
12:40

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System

Published on: December 7, 2012

Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

Alternative Methods for the Detection of Superoxide Anion Generation in Platelets
06:35

Alternative Methods for the Detection of Superoxide Anion Generation in Platelets

Published on: March 29, 2024

Área de la Ciencia:

  • Química supramolecular de las moléculas.
  • Química biofísica y bioquímica.
  • Biología Estructural Biología estructural.

Sus antecedentes:

  • El autoensamblaje de péptidos es crucial para las estructuras biológicas.
  • El diseño de complejos estables péptido-ADN sigue siendo un desafío.
  • Comprender las interacciones moleculares guía el desarrollo de nuevos biomateriales.

Objetivo del estudio:

  • Para investigar la formación y la estabilidad de duplexos híbridos péptido-ADN.
  • Para explorar las consecuencias estructurales de la fijación de cadenas tripeptídicas a una plantilla de ADN.
  • Para caracterizar el comportamiento de autoensamblaje de péptidos con y sin un andamio de ADN.

Principales métodos:

  • Síntesis de cuatro cadenas tripeptídicas y un dúplex de ADN complementario.
  • Formación de duplexos híbridos mediante la unión de péptidos al ADN. termini.
  • Caracterización estructural utilizando espectroscopia de Resonancia Magnética Nuclear (RMN) en 1D y 2D.
  • Análisis termodinámico a través de la calorimetría de titulación isotérmica (ITC).

Principales resultados:

  • Cuatro duplexos híbridos distintos (1a.2a, 1a.2b, 1b.2a, 1b.2b) se forman cuando los péptidos se unen al mismo extremo del ADN, con segmentos de hoja beta de dos hebras.
  • La RMN confirmó conformaciones extendidas de péptidos, estabilizadas por enlaces de hidrógeno e interacciones de cadena lateral.
  • La plantilla de ADN inhibió una mayor agregación de péptidos.
  • La unión a diferentes terminales de ADN dio lugar a conformaciones indefinidas, mientras que los péptidos por sí solos mostraron una asociación aleatoria.
  • ITC reveló que el dúplex híbrido 1a.2a era termodinámicamente más estable que la plantilla de ADN o los péptidos solos.

Conclusiones:

  • Las cadenas de péptidos pueden formar duplexos híbridos estables y ricos en hojas beta con plantillas de ADN.
  • El dúplex de ADN actúa como un andamio, dirigiendo el ensamblaje de péptidos y evitando la agregación.
  • Los dúplex híbridos exhiben una mayor estabilidad, ofreciendo potencial para el diseño de nuevos sistemas de autoensamblaje.